Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Dai ichi Life Insurance Company Ltd decreased its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 13.6% during the 3rd quarter, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Dai-ichi Life Insurance Co. lost about ¥140 billion ($890 million) selling off bonds with longer maturities to prepare for ...

Multiple Japanese companies have suspended commercials on Fuji Television Network following a scandal involving ...

In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...

The planned bonds are expected to have a call option after 10 years. Fitch Ratings anticipates Dai-ichi Life's financial ...